Paul D Nathan (Paul Nathan)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Metastatic Colorectal Cancer

Small Cell Lung Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Therapeutic advances in medical oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Fiona J Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul D Nathan, Robert J Jones, David M Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie B Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo A Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky J Goh, David L Buckley, Jenny Hewison, Walter Martin Gregory, Peter John Selby, Julia M Brown, Janet E Brown, null null
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health technology assessment (Winchester, England) 28 (45) (2024)
Sarah Howlett, Thomas J Carter, Heather M Shaw, Paul D Nathan
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Therapeutic advances in medical oncology 15 (2023)
Naveen S Vasudev, Gemma Ainsworth, Sarah R Brown, Lisa M Pickering, Tom Waddell, Kate Fife, Richard Griffiths, Anand Sharma, Eszter Katona, Helen Howard, Galina Velikova, Anthony Maraveyas, Janet Brown, Carmel Pezaro, Mark Tuthill, Ekaterini Boleti, Amit Bahl, Bernadett Szabados, Rosamonde E Banks, Joanne Brown, Balaji Venugopal, Poulam Manubhai Patel, Ankit Jain, Stefan N Symeonides, Paul D Nathan, Fiona J Collinson, Thomas Powles
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sarah Howlett, Thomas J Carter, Heather M Shaw, Paul D Nathan
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Therapeutic advances in medical oncology 15 (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Richard D Carvajal, Paul D Nathan, Joseph J Sacco, Marlana Orloff, Leonel F Hernandez-Aya, Jessica Yang, Jason John Luke, Marcus O Butler, Sarah Stanhope, Laura Collins, Cheryl McAlpine, Chris Holland, Shaad E Abdullah, Takami Sato
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (17) (2022)
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo Antonio Ascierto, Paul D Nathan, Piotr Lukasz Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandala, Paul C Lorigan, Pier Francesco Ferrucci, Jean-Jacques Grob, Nicolas Meyer, Helen J Gogas, Daniil Stroyakovskiy, Ana M Arance, Jan C Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (13) (2022)